The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy

Zhang,Rui; Sun,Xin; Niu,Bo

doi:10.3892/etm.2017.5307

The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy

Authors:
- Rui Zhang
- Xin Sun
- Bo Niu
View Affiliations

Affiliations: Physical Examination Department, Sino‑Singapore Eco‑City Hospital of Tianjin Medical University, Eco‑City, Tianjin 300467, P.R. China, Shanghai Institute of Cancer, Shanghai Jiaotong University School of Medicine, Shanghai 200240, P.R. China
Published online on: October 16, 2017 https://doi.org/10.3892/etm.2017.5307
Pages: 6002-6006
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to report the importance of pegaptanib sodium (PGSD) injection treatment for vascular active vitreoretinopathy (VAVR). A total of 82 patients with VAVR diagnosed by increasing subretinal exudation were enrolled and received a single intravitreal injection of PGSD. The efficacies of PGSD for patients with VAVR were analyzed using photography, fluorescein angiography and optical coherence tomography. The pathological changes in vascular activity, amount of exudation and visual acuity between the PGSD, and placebo group were also compared. The results demonstrated that the PGSD injection significantly decreased subretinal exudation and leakage compared with the placebo when assessed using fluorescein angiography in a 12‑month follow‑up. It was observed that the PGSD injection inhibited inflammatory cytokines interleukin‑1β and tumor necrosis factor α for patients with VAVR compared with the placebo. Furthermore, results demonstrated that the average inflammation score and intraocular pressure was significantly decreased compared with the placebo. Visual acuity was improved from 1.3 to 0.7 in the majority of patients in the PGSD group. In conclusion, the outcomes of the present study indicate that the PGSD intravitreal injection is an efficient treatment option for patients with VAVR.

View Figures

View References

1	Gandhi JK, Tollefson TT and Telander DG: Falciform macular folds and chromosome 22q11.2: Evidence in support of a locus for familial exudative vitreoretinopathy (FEVR). Ophthalmic Genet. 35:112–116. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pennock S, Haddock LJ, Mukai S and Kazlauskas A: Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy. Am J Pathol. 184:3052–3068. 2014. View Article : Google Scholar : PubMed/NCBI
3	Radke NV, Panakanti TK, Radke SN and Ravikoti R: Comment on ‘Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy’. Eye (Lond). 28:15252014. View Article : Google Scholar : PubMed/NCBI
4	Robitaille JM, Gillett RM, LeBlanc MA, Gaston D, Nightingale M, Mackley MP, Parkash S, Hathaway J, Thomas A, Ells A, et al: Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by KIF11 mutations. JAMA Ophthalmol. 132:1393–1399. 2014. View Article : Google Scholar : PubMed/NCBI
5	Shi H, Guo T, Liu PC, Wang QY, Du YR, Liu QY, He MM, Liu JL and Yu J: Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: A systematic review and meta-analysis. Drug Des Devel Ther. 9:1393–1400. 2015.PubMed/NCBI
6	Chiquet C and Rouberol F: Proliferative vitreoretinopathy: Curative treatment. J Fr Ophtalmol. 37:653–659. 2014.(In French). View Article : Google Scholar : PubMed/NCBI
7	Quiram PA, Drenser KA, Lai MM, Capone A Jr and Trese MT: Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina. 28 3 Suppl:S8–S12. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hussar DA: New drugs: Entecavir, ibandronate sodium, and pegaptanib sodium. J Am Pharm Assoc (2003). 45:412–415. 2005. View Article : Google Scholar : PubMed/NCBI
9	Moshfeghi AA and Puliafito CA: Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 14:671–682. 2005. View Article : Google Scholar : PubMed/NCBI
10	Gonzales CR: VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina. 25:815–827. 2005. View Article : Google Scholar : PubMed/NCBI
11	Shukla D, Namperumalsamy P, Goldbaum M and Cunningham ET Jr: Pegaptanib sodium for ocular vascular disease. Indian J Ophthalmol. 55:427–430. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rouberol F and Chiquet C: Proliferative vitreoretinopathy: Pathophysiology and clinical diagnosis. J Fr Ophtalmol. 37:557–565. 2014.(In French). View Article : Google Scholar : PubMed/NCBI
13	Lane SS and Holland EJ: Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 39:168–173. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wolfe JD and Hubbard GB III: Spontaneous regression of subretinal exudate in coats disease. Arch Ophthalmol. 124:1208–1209. 2006. View Article : Google Scholar : PubMed/NCBI
15	Rodriguez A, Rodriguez FJ, Valencia M and Castaño C: Late development of a lamellar macular hole after the spontaneous separation of vitreoretinal traction: Case report. Eur J Ophthalmol. 26:e168–e170. 2016. View Article : Google Scholar : PubMed/NCBI
16	Rodriguez A, Valencia M and Gomez FE: Vitreoretinal traction and lamellar macular holes associated with cicatricial toxoplasmic retinochoroiditis: Case series report. Eur J Ophthalmol. 26:e128–e133. 2016. View Article : Google Scholar : PubMed/NCBI
17	Feist RM Jr, King JL, Morris R, Witherspoon CD and Guidry C: Myofibroblast and extracellular matrix origins in proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 252:347–357. 2014. View Article : Google Scholar : PubMed/NCBI
18	Tosi GM, Marigliani D, Romeo N and Toti P: Disease pathways in proliferative vitreoretinopathy: An ongoing challenge. J Cell Physiol. 229:1577–1583. 2014. View Article : Google Scholar : PubMed/NCBI
19	Lipski A, Bornfeld N and Jurklies B: Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium. Retina. 27:864–872. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ulinska M: Pegaptanib sodium in treatment of wet AMD. Klin Oczna. 108:482–488. 2006.(In Polish). PubMed/NCBI
21	Foy JW, Rittenhouse K, Modi M and Patel M: Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J Ocul Pharmacol Ther. 23:452–466. 2007. View Article : Google Scholar : PubMed/NCBI
22	Rinaldi M, Chiosi F, Dell'Omo R, Romano MR, Parmeggiani F, Semeraro F, Menzione M and Costagliola C: Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: A morphologic and functional study. Retina. 33:397–402. 2013. View Article : Google Scholar : PubMed/NCBI
23	Ishibashi T: LEVEL-J Study Group: Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: An exploratory study in Japanese patients (LEVEL-J study). Jpn J Ophthalmol. 57:417–423. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ng EW and Adamis AP: Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci. 1082:151–171. 2006. View Article : Google Scholar : PubMed/NCBI
25	Moysidis SN, Thanos A and Vavvas DG: Mechanisms of inflammation in proliferative vitreoretinopathy: From bench to bedside. Mediators Inflamm. 2012:8159372012. View Article : Google Scholar : PubMed/NCBI
26	Dombi T, Kwok KK and Sultan MB: A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus. BMC Ophthalmol. 12:372012. View Article : Google Scholar : PubMed/NCBI
27	Tikhonovich MV, Iojleva EJ and Gavrilova SA: The role of inflammation in the development of proliferative vitreoretinopathy. Klin Med (Mosk). 93:14–20. 2015.(In Russian). PubMed/NCBI
28	Rojas J, Fernandez I, Pastor JC, Maclaren RE, Ramkissoon Y, Harsum S, Charteris DG, Van Meurs JC, Amarakoon S, Ruiz-Moreno JM, et al: A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 54:1665–1678. 2013. View Article : Google Scholar : PubMed/NCBI
29	Keane-Myers AM, Miyazaki D, Liu G, Dekaris I, Ono S and Dana MR: Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci. 40:3041–3046. 1999.PubMed/NCBI
30	Hocaoglu M, Karacorlu M, Sayman Muslubas I, Ersoz MG and Arf S: Anatomical and functional outcomes following vitrectomy for advanced familial exudative vitreoretinopathy: A single surgeon's experience. Br J Ophthalmol. 101:946–950. 2016. View Article : Google Scholar : PubMed/NCBI
31	Tikhonovich M, Lyskin P, Ioyleva E and Gavrilova S: Expression of cyclooxygenases and trophic and growth factors in epiretinal membranes at late stages of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 254:2277–2279. 2016. View Article : Google Scholar : PubMed/NCBI
32	Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK and Riemann CD: Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol. 10:1811–1817. 2016. View Article : Google Scholar : PubMed/NCBI